Abstract
Robust non-invasive biomarker assays are needed to improve patient selection and pharmacodynamic assessments for PARP inhibitors as the currently accepted biomarkers (e.g. BRCA1/2 mutations) results in variability in response and benefit. [18F] Fluorthanatrace (FTT) is a positron emission tomography (PET) tracer that has been previously demonstrated to measure in vivo PARP1 expression in breast and ovarian cancers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.